Fig. 2.

2-A showed the depiction of random blood glucose levels of all the experimental mice models. 2-B illustrated the glucose tolerance test results of all experimental groups over time i.e. from 0 level to 180 min. Scopolamine-treated group in comparison to all other groups expressed high level of glucose in blood while scopolamine plus folicitin-injected group showed less concentration of blood glucose elucidating the neuroprotective capability of folicitin.